Zentalis Pharmaceuticals, Inc.
ZNTL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ZNTL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ZNTL
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing azenosertib, a potential WEE1 inhibitor, for cancer treatment, with ongoing Phase 2 and Phase 3 trials and a cash runway into late 2027.
Key risk: Single product dependency
BioSniper Score
Based on 6 of 6 signals
Market Cap
$359.8M
Cash Runway
13.8 moLead Asset
azenosertib (ZN-c3) (Phase 3)Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 10 clinical trials · 2 catalysts for Zentalis Pharmaceuticals, Inc..
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing azenosertib, a potential WEE1 inhibitor, for cancer treatment, with ongoing Phase 2 and Phase 3 trials and a cash runway into late 2027.
- Zentalis is primarily developing azenosertib, a WEE1 inhibitor, for patients with Cyclin E positive tumors [sec_mda · as of 2026-05-12].
- As of June 30, 2026, the company reported cash & equivalents of $27.4M, net income of -$42.3M, and shareholders' equity of $274.5M [sec].
- The company believes its existing cash, cash equivalents and marketable securities as of March 31, 2026 will be sufficient to fund operating expenses and capital expenditure requirements into late 2027 [sec_mda · as of 2026-05-12].
- Zentalis has a Phase 2 topline readout for azenosertib expected by December 31, 2026, and a Phase 3 topline readout expected by April 30, 2030 [catalyst].
- The company underwent a strategic restructuring in January 2025, which led to non-recurring expenses and a subsequent decrease in research and development expenses through the third quarter of 2025 [sec_mda · as of 2025-11-10].
What works
- Zentalis has a clear late-stage clinical focus on azenosertib, with both a Phase 2 and a Phase 3 trial underway, providing multiple potential catalysts [catalyst].
- The company's cash runway extends into late 2027, providing a multi-year operational buffer to advance its lead program without near-term financing pressure [sec_mda · as of 2026-05-12].
- The strategic restructuring in early 2025 has reduced operating expenses, potentially extending the company's financial runway and improving operational efficiency [sec_mda · as of 2025-11-10].
What to weigh
- Zentalis has a limited operating history and has not yet generated any product revenue, making it difficult to evaluate its future business prospects [sec · filed 2025-01-28].
- The company reported a net loss of $42.3M for the quarter ended June 30, 2026, reflecting ongoing high research and development costs [sec].
- The successful development and commercialization of azenosertib is highly uncertain, and the company may need additional funding sooner than expected if clinical trials are delayed or require more resources [sec_mda · as of 2026-05-12].
- Zentalis is heavily dependent on the success of a single product candidate, azenosertib, which exposes it to significant clinical and regulatory risk [sec_mda · as of 2026-05-12].
From the filings
Quoted directly from source documents.
Cash runway into late 2027
“We believe that our existing cash, cash equivalents and marketable securities as of March 31, 2026 will be sufficient to fund our operating expenses and capital expenditure requirements into late 2027.”
SEC MD&A · May 12, 2026
Strategic restructuring in January 2025
“Following the strategic restructuring announced in January 2025, we incurred certain associated non-recurring expenses in the first quarter of 2025.”
SEC MD&A · November 10, 2025
Limited operating history and forward-looking risks
“the Company's limited operating history, which may make it difficult to evaluate the Company's current business and predict the Company's future success”
SEC filings · January 28, 2025
Azenosertib development for Cyclin E positive tumors
“the progress, costs and results of our clinical trials for azenosertib for patients with Cyc”
SEC MD&A · May 12, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · azenosertib — Phase 2 Readout: azenosertib — Topline data from the Phase 2 study of azenosertib will be released, providing key efficacy and safety data.
- 2030-04-30 · Phase3_Topline · azenosertib — Phase 3 Topline: A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy i — Topline results from the randomized Phase 3 study comparing azenosertib to chemotherapy will be disclosed, a pivotal milestone for potential registration.
Risks & what to watch (4)›
Key risks
- Single product dependency — Zentalis is heavily reliant on the success of azenosertib; failure in clinical trials would severely impact the company [sec_mda · as of 2026-05-12].
- No approved products or revenue — The company has no commercial products and has not generated any revenue from product sales, relying solely on financing [sec · filed 2025-01-28].
- Clinical trial uncertainty — The costs and outcomes of clinical trials for azenosertib are highly uncertain and could require more capital than expected [sec_mda · as of 2026-05-12].
- Limited operating history — Zentalis has a limited operating history, making it difficult to evaluate its business and predict future success [sec · filed 2025-01-28].
What to watch
- Phase 2 topline data for azenosertib expected by December 31, 2026, which will provide initial efficacy and safety signals [catalyst].
- Phase 3 topline data for azenosertib expected by April 30, 2030, a pivotal readout that could support regulatory filing [catalyst].
- Cash burn rate and any updates to the cash runway, especially as the company advances later-stage trials [sec_mda · as of 2026-05-12].
- Any updates on the strategic restructuring and its impact on operating expenses and pipeline prioritization [sec_mda · as of 2025-11-10].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Zentalis Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Zentalis Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
13.8 months
D/E 0.50 · 0% dilution
Lead: Phase 3
1 candidate
2 upcoming, next in ~123d
1 buy · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
98
Total value held
$75.7M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,621,414 | $10.8M |
| two sigma investments, lp | 2,956,526 | $6.9M |
| renaissance technologies llc | 1,938,145 | $4.5M |
| citadel advisors llc | 1,756,283 | $4.1M |
| d. e. shaw & co., inc. | 1,484,098 | $3.5M |
| millennium management llc | 1,289,822 | $3.0M |
| blackrock, inc. | 1,269,837 | $3.0M |
| ishara investments lp | 1,230,000 | $2.9M |
| bank of america corp /de/ | 1,132,294 | $2.6M |
| primecap management co/ca/ | 957,420 | $2.2M |
Showing top 10 of 98 institutional holders of Zentalis Pharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 9.6%
- Days to cover
- 1.4
- Shares short
- 5,488,269
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ZNTL short interestGovernance
Frequently asked questions
What is the AI investment thesis for Zentalis Pharmaceuticals, Inc.?
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing azenosertib, a potential WEE1 inhibitor, for cancer treatment, with ongoing Phase 2 and Phase 3 trials and a cash runway into late 2027.
What is Zentalis Pharmaceuticals, Inc.'s lead drug candidate?
Zentalis Pharmaceuticals, Inc.'s most advanced tracked candidate is azenosertib (ZN-c3) (Phase 3) for Solid Tumor; Osteosarcoma; Uterine Serous Carcinoma.
What is Zentalis Pharmaceuticals, Inc.'s next catalyst?
Zentalis Pharmaceuticals, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: azenosertib" — expected December 31, 2026.
Who is the CEO of Zentalis Pharmaceuticals, Inc.?
Ms. Julie M. Eastland M.B.A. is the chief executive officer of Zentalis Pharmaceuticals, Inc. (ZNTL).
Where is Zentalis Pharmaceuticals, Inc. headquartered?
Zentalis Pharmaceuticals, Inc. (ZNTL) is headquartered in San Diego, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.